NO932857L - Forbedret blodsubstitutt - Google Patents

Forbedret blodsubstitutt

Info

Publication number
NO932857L
NO932857L NO93932857A NO932857A NO932857L NO 932857 L NO932857 L NO 932857L NO 93932857 A NO93932857 A NO 93932857A NO 932857 A NO932857 A NO 932857A NO 932857 L NO932857 L NO 932857L
Authority
NO
Norway
Prior art keywords
blood substitute
periodate
electrolytes
atp
adenosine
Prior art date
Application number
NO93932857A
Other languages
English (en)
Other versions
NO308934B1 (no
NO932857D0 (no
Inventor
Mario Feola
Jan S Simoni
Original Assignee
Univ Texas Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas Tech filed Critical Univ Texas Tech
Publication of NO932857D0 publication Critical patent/NO932857D0/no
Publication of NO932857L publication Critical patent/NO932857L/no
Publication of NO308934B1 publication Critical patent/NO308934B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026Blood substitute; Oxygen transporting formulations; Plasma extender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445Haemoglobin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/805Haemoglobins; Myoglobins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Cosmetics (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
NO932857A 1991-02-12 1993-08-11 FremgangsmÕte for fremstilling av et preparat egnet for anvendelse som et blodsubstitutt NO308934B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65476491A 1991-02-12 1991-02-12
PCT/US1991/009384 WO1992013875A1 (en) 1991-02-12 1991-12-13 Improved blood substitute

Publications (3)

Publication Number Publication Date
NO932857D0 NO932857D0 (no) 1993-08-11
NO932857L true NO932857L (no) 1993-10-12
NO308934B1 NO308934B1 (no) 2000-11-20

Family

ID=24626150

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932857A NO308934B1 (no) 1991-02-12 1993-08-11 FremgangsmÕte for fremstilling av et preparat egnet for anvendelse som et blodsubstitutt

Country Status (10)

Country Link
EP (1) EP0586381B1 (no)
JP (1) JP3437572B2 (no)
KR (1) KR100227453B1 (no)
AT (1) ATE173273T1 (no)
AU (1) AU656763B2 (no)
CA (1) CA2103680C (no)
DE (1) DE69130483T2 (no)
FI (1) FI106362B (no)
NO (1) NO308934B1 (no)
WO (1) WO1992013875A1 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0767675A4 (en) * 1995-04-10 1998-08-05 Baxter Int USE OF CROSS-LINKED HEMOGLOBIN IN THE TREATMENT OF SUBARACHNOIDAL BLEEDING
EP1660133B1 (en) * 2003-05-15 2018-04-18 Therapure Biopharma Inc. Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
KR102384708B1 (ko) * 2020-06-19 2022-04-11 대한민국 혈흔형태분석용 인공혈액

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4401652A (en) * 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
US4473496A (en) * 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
DE3714351A1 (de) * 1987-04-29 1988-11-17 Barnikol Wolfgang Verfahren zur modifikation, insbesondere zur polymerisation von haemoglobin in vitro
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
ATE136466T1 (de) * 1989-12-29 1996-04-15 Univ Texas Tech Polyhämoglobin durch purinderivate und glutathion stabilisiert

Also Published As

Publication number Publication date
FI933550L (fi) 1993-08-11
JP3437572B2 (ja) 2003-08-18
AU1270492A (en) 1992-09-07
FI933550A0 (fi) 1993-08-11
DE69130483D1 (de) 1998-12-17
AU656763B2 (en) 1995-02-16
EP0586381A1 (en) 1994-03-16
WO1992013875A1 (en) 1992-08-20
CA2103680A1 (en) 1992-08-20
JP2002507185A (ja) 2002-03-05
EP0586381A4 (en) 1994-09-14
KR100227453B1 (ko) 1999-11-01
ATE173273T1 (de) 1998-11-15
FI106362B (fi) 2001-01-31
DE69130483T2 (de) 1999-06-10
NO308934B1 (no) 2000-11-20
NO932857D0 (no) 1993-08-11
CA2103680C (en) 1999-11-23
EP0586381B1 (en) 1998-11-11

Similar Documents

Publication Publication Date Title
DK0430045T3 (da) Ascorbinsyretocopherylphosphatdiestere til hæmning af Maillards reaktion
Friedl et al. Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients
FI922937A0 (fi) Polyhemoglobin stabiliserad med purinderivat och glutation.
KR950700752A (ko) 유장단백질로 hiv-혈청양성개체의 치료방법
DK0559655T3 (da) Med imidoester tværbundne hæmoglobinpræparater
CA2154080A1 (en) Novel anticoagulant cofactor activity
ATE271560T1 (de) Verbindungen mit antiviraler aktivität
MX9200882A (es) Preparacion de factor ix.
FI933550A0 (fi) Foerbaettrat blodsubstitut
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
AU652988B2 (en) Method for insuring adequate intracellular glutathione in tissue
EA200200535A1 (ru) Применение треосульфана для подготовки пациентов перед трансплантацией костного мозга или трансплантацией стволовых клеток крови
RU96109508A (ru) Способ лечения отравлений, вызванных фосфороорганическими веществами
Roth Jr et al. A and S radioactive 14C-HN2 is located in the first tryptic peptide
JPS6468328A (en) Anticorneoulcerative
ITMI922040A1 (it) Composizioni farmaceutiche per il trattamento di stati di iperaggregabilita' piastrinica

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees